EMN29

Title

A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Overview / Summary

Study details

Participating countries include:

Germany (9 sites – Prof.  Katja Weisel from Hamburg as study PI and country coordinator)

Italy (19 sites – Prof. Antonietta Falcone from San Giovanni Rotondo as country coordinator)

Greece (5 sites – Prof. Evangelos Terpos from Athens as country coordinator)

France (7 sites – Prof. Philippe Moreau from Nantes as country coordinator)

Netherland (2 sites – Prof. Ruth Wester from Rotterdam as country coordinator)

Spain (10 sites – Prof. Paula Rodriguez Otero from Pamplona as country coordinator)

USA (35 sites)

Patient eligibility criteria

Pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an IMiD, PI and an anti-CD38 mAb.

Publications